Compare Stocks

→ “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGLE Aeglea BioTherapeutics		$11.47	$2.66 ▼ $32.75	$48.64M	2.57	95,409 shs	43,300 shs
EVLO Evelo Biosciences	$0.05	$0.05	$0.03 ▼ $13.93	$868K	2.03	40,811 shs	488 shs
NBSE NeuBase Therapeutics	$0.44 +4.7%	$0.68	$0.39 ▼ $4.80	$1.66M	0.83	202,576 shs	25,441 shs
OASM Oasmia Pharmaceutical AB (publ)	$0.02	$1.46	$0.94 ▼ $5.70	$1.50M	0.96	98,414 shs	N/A

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGLE Aeglea BioTherapeutics	0.00%	0.00%	0.00%	0.00%	+199.13%
EVLO Evelo Biosciences	+3.39%	-8.60%	-8.60%	-29.69%	-97.72%
NBSE NeuBase Therapeutics	+4.99%	+4.15%	-7.69%	-29.90%	-82.87%
OASM Oasmia Pharmaceutical AB (publ)	0.00%	0.00%	0.00%	0.00%	-60.00%

“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)

Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.

Find out why right here (and see what you can do to get in too with just a few dollars).

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGLE Aeglea BioTherapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EVLO Evelo Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OASM Oasmia Pharmaceutical AB (publ)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGLE Aeglea BioTherapeutics	2.50	Moderate Buy	$17.50	∞ Upside
EVLO Evelo Biosciences	2.00	Hold	N/A	N/A
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A
OASM Oasmia Pharmaceutical AB (publ)	N/A	N/A	N/A	N/A

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGLE Aeglea BioTherapeutics	$2.33M	0.00	N/A	N/A	($60.61) per share	0.00
EVLO Evelo Biosciences	N/A	N/A	N/A	N/A	($0.92) per share	N/A
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A	$11.04 per share	N/A
OASM Oasmia Pharmaceutical AB (publ)	$220K	6.82	N/A	N/A	$0.63 per share	0.03

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGLE Aeglea BioTherapeutics	-$83.82M	-$75.59	N/A	N/A	N/A	-22,195.36%	-132.05%	-146.87%	N/A
EVLO Evelo Biosciences	-$114.53M	-$13.29	N/A	∞	N/A	N/A	N/A	-189.58%	5/13/2024 (Estimated)
NBSE NeuBase Therapeutics	-$4.37M	-$7.70	N/A	∞	N/A	N/A	-99.74%	-60.13%	5/9/2024 (Estimated)
OASM Oasmia Pharmaceutical AB (publ)	-$18.95M	N/A	0.00	∞	N/A	-8,633.64%	-43.94%	-28.92%	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGLE Aeglea BioTherapeutics	N/A	N/A	N/A	N/A	N/A
EVLO Evelo Biosciences	N/A	N/A	N/A	N/A	N/A
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A	N/A
OASM Oasmia Pharmaceutical AB (publ)	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGLE Aeglea BioTherapeutics	N/A	4.59	4.59
EVLO Evelo Biosciences	N/A	0.48	0.48
NBSE NeuBase Therapeutics	N/A	2.87	2.87
OASM Oasmia Pharmaceutical AB (publ)	N/A	0.80	0.73

Ownership

Institutional Ownership

Company	Institutional Ownership
AGLE Aeglea BioTherapeutics	N/A
EVLO Evelo Biosciences	0.31%
NBSE NeuBase Therapeutics	12.37%
OASM Oasmia Pharmaceutical AB (publ)	0.11%

Insider Ownership

Company	Insider Ownership
AGLE Aeglea BioTherapeutics	6.60%
EVLO Evelo Biosciences	1.02%
NBSE NeuBase Therapeutics	13.90%
OASM Oasmia Pharmaceutical AB (publ)	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AGLE Aeglea BioTherapeutics	69	4.05 million	3.78 million	Optionable
EVLO Evelo Biosciences	66	18.98 million	18.79 million	No Data
NBSE NeuBase Therapeutics	37	3.75 million	3.23 million	Not Optionable
OASM Oasmia Pharmaceutical AB (publ)	57	74.97 million	N/A	Not Optionable

AGLE, NBSE, OASM, and EVLO Headlines

Source	Headline
	Lipigon Pharmaceuticals AB LPGO morningstar.com - March 23 at 12:53 AM
	LSK BioPartners, Inc., Oasmia Pharmaceutical AB (publ) - Special Call Transcript gurufocus.com - March 6 at 9:00 AM
	Oasmia Pharmaceutical AB (publ) - Special Call Transcript gurufocus.com - March 6 at 9:00 AM
	Resurs Holding AB (publ) (RESURS.ST) finance.yahoo.com - February 8 at 12:32 AM
	QuiaPEG Pharmaceuticals Holding AB QUIA morningstar.com - January 6 at 5:30 PM
	Newbury Pharmaceuticals AB (NEWBRY) investing.com - November 29 at 2:08 AM
	Dentsu Creative bags mandate for Torrent Pharmaceuticals’ Shelcal & Unienzyme bestmediainfo.com - September 26 at 1:06 AM
	Lipigon Pharmaceuticals AB (LPGO) investing.com - September 14 at 9:09 AM
	Speqta publ AB (SPEQT) investing.com - August 25 at 9:50 PM
	PRXXF Paradox Interactive AB (publ) seekingalpha.com - August 25 at 9:29 AM
	Notice of annual general meeting in Alzinova AB (publ) privataaffarer.se - April 25 at 8:37 AM
	Report from Annual General Meeting 2023 of PowerCell Sweden AB (publ) privataaffarer.se - April 21 at 8:26 PM
	Notice of Annual General Meeting 2023 in Enzymatica AB (publ) (2) europapress.es - April 2 at 9:53 AM
	OXE Marine AB (publ) Non-GAAP EPS of -SEK0.43, revenue of SEK32.2M seekingalpha.com - February 26 at 11:56 PM
	US regulators clear way for more monkeypox vaccine shipments starherald.com - July 14 at 11:12 AM
	PRELIMINARY RESULT OF OASMIA’S RIGHTS ISSUE (MFN) avanza.se - March 24 at 6:47 AM
	Oasmia expands R&D ability with planned laboratory upgrade privataaffarer.se - March 17 at 8:40 AM
	Orexo appoints Fredrik Järrsten as new CFO stockhouse.com - March 11 at 3:47 AM
	Notice of extra general meeting in Terranet AB finanznachrichten.de - November 29 at 10:24 AM
	Pet Cancer Therapeutics Market – Know-How Industry to Experience Positive Growth \| robust CAGR of 7.7% over the forecast period (2017 – 2025). medgadget.com - September 17 at 2:52 AM
	Veterinary Cancer Therapeutics Market Segmentation, Size Analysis, Key Players Forecast To 2027 openpr.com - July 28 at 7:04 PM
	Fancy Wood Industries PCL (FANCY) investing.com - July 22 at 7:07 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian benchmarks mostly climb despite worries about US economy
April 25, 2024 2:14 AM
View Stock market today: Asian benchmarks mostly climb despite worries about US economy
Foot Locker Builds Up Another Head of Steam; Gains Imminent
March 28, 2024 10:58 AM
View Foot Locker Builds Up Another Head of Steam; Gains Imminent
3 Value Stocks Buffett Wishes He Could Buy
April 22, 2024 8:35 AM
View 3 Value Stocks Buffett Wishes He Could Buy
Gold Rush: Exploring 5 Sector Giants Amidst Soaring Prices
April 4, 2024 6:10 AM
View Gold Rush: Exploring 5 Sector Giants Amidst Soaring Prices

All Headlines

Company Descriptions

Aeglea BioTherapeutics

NASDAQ:AGLE

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Evelo Biosciences

NASDAQ:EVLO

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

NeuBase Therapeutics

NASDAQ:NBSE

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

Oasmia Pharmaceutical AB (publ)

NASDAQ:OASM

Oasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial